カテゴリ： GlobalData, 中国, 企業調査

China National Pharmaceutical Group Corp-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：China National Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014052
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：68
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：中国
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
China National Pharmaceutical Group Corp (Sinopharm) is a provider of medical and healthcare services. Its core businesses include the distribution, retailing, research and manufacture of healthcare related products. Its product portfolio includes EPI vaccines; biopharmaceutical products; anaesthetics and psychotropics; anti-infective, anti-tumor, cardiovascular and respiratory system drugs; and medicinal herbs. Its business activities include manufacturing and R&D, pharmaceutical logistics and distribution, pharmacy retail chain, anaesthetic distribution, cold-chain distribution for biological products and medical equipment, and distribution of consumable materials, modern and traditional Chinese medicines, besides medical scientific research, engineering design and pharmaceutical international trade. The company has operations across China. Sinopharm is headquartered in Haidian, Beijing, China.

China National Pharmaceutical Group Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 15
Partnerships 16
Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16
Chi-Med Forms Joint Venture with Sinopharm 17
Mitsubishi Forms Joint Venture With Sinopharm 18
China NT Pharma To Form Joint Venture With Sinopharm 19
China State Institute of Pharma Enters Into Research Agreement With Sanofi 20
Aeras Enters Into Co-Development Agreement With China National Biotech Group 21
University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 22
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 23
Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 24
Licensing Agreements 25
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 25
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 26
Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 28
Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 30
Equity Offering 31
Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 31
Sinopharm to Raise USD728 Million in Private Placement of Shares 32
Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 34
Sinopharm Completes Private Placement Of Shares For US$525 Million 35
China National Biotech Plans To Complete IPO For US$1.5 Billion 37
Debt Offering 38
Sinopharm Group Plans Public Offering Of Bonds For US$633 Million 38
China National Biotec Plans Public Offering Of Notes Due 2015 For US$126 Million 39
Sinopharm Group Announces Private Placement Of Medium Term Bonds For US$466 Million 40
Sinopharm Group Completes Private Placement Of Medium Term Bonds For US$308 Million 41
Acquisition 42
China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 42
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 43
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 44
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million 45
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 46
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million 48
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million 49
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 50
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million 51
China National Pharma Acquires 37.1% Stake In Winteam Pharma For US$32.5 Million 52
Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For US$3.3 Million 54
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million 55
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million 56
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million 57
Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For US$33 Million 58
China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For US$1.4 Million 59
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 60
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 61
Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 62
China National Pharmaceutical Group Corp – Key Competitors 63
China National Pharmaceutical Group Corp – Key Employees 64
China National Pharmaceutical Group Corp – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 2
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
China National Pharmaceutical Group Corp, Deals By Therapy Area, 2011 to YTD 2017 10
China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 15
Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16
Chi-Med Forms Joint Venture with Sinopharm 17
Mitsubishi Forms Joint Venture With Sinopharm 18
China NT Pharma To Form Joint Venture With Sinopharm 19
China State Institute of Pharma Enters Into Research Agreement With Sanofi 20
Aeras Enters Into Co-Development Agreement With China National Biotech Group 21
University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 22
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 23
Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 24
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 25
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 26
Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 28
Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 30
Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 31
Sinopharm to Raise USD728 Million in Private Placement of Shares 32
Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 34
Sinopharm Completes Private Placement Of Shares For US$525 Million 35
China National Biotech Plans To Complete IPO For US$1.5 Billion 37
Sinopharm Group Plans Public Offering Of Bonds For US$633 Million 38
China National Biotec Plans Public Offering Of Notes Due 2015 For US$126 Million 39
Sinopharm Group Announces Private Placement Of Medium Term Bonds For US$466 Million 40
Sinopharm Group Completes Private Placement Of Medium Term Bonds For US$308 Million 41
China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 42
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 43
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 44
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million 45
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 46
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million 48
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million 49
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 50
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million 51
China National Pharma Acquires 37.1% Stake In Winteam Pharma For US$32.5 Million 52
Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For US$3.3 Million 54
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million 55
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million 56
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million 57
Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For US$33 Million 58
China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For US$1.4 Million 59
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 60
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 61
Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 62
China National Pharmaceutical Group Corp, Key Competitors 63
China National Pharmaceutical Group Corp, Key Employees 64
China National Pharmaceutical Group Corp, Subsidiaries 65

★海外企業調査レポート[China National Pharmaceutical Group Corp-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Cumberland Pharmaceuticals Inc (CPIX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Cumberland Pharmaceuticals Inc (Cumberland Pharma) is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products. Its primary target markets are hospital acute care, gastroenterology and cancer supportive care. The company offers branded presc …
  • GFT Technologies AG (GFT)：企業の財務・戦略的SWOT分析
    Summary GFT Technologies AG (GFT Technologies) is a technology company that implements, develops, and maintains information technology solutions. The company’s services comprise application management, bespoke development, product based implementation, and business and IT consultation services. GFT …
  • Noni B Ltd (NBL)：企業の財務・戦略的SWOT分析
    Noni B Ltd (NBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • H.I.G. Capital LLC：企業の戦略的SWOT分析
    H.I.G. Capital LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • ICICI Lombard General Insurance Company Limited：企業の戦略・SWOT・財務情報
    ICICI Lombard General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary ICICI Lombard General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Silex Systems Ltd (SLX)：企業の財務・戦略的SWOT分析
    Summary Silex Systems Ltd (Silex) is a research and development company that offers technology solutions. The company develops, and commercializes technologies in solar energy, nuclear energy, and advanced materials and instrumentation. It develops utility-scale concentrating photovoltaic technology …
  • Operation Technology Inc：企業の戦略的SWOT分析
    Operation Technology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Slovensky plynarensky priemysel AS：企業の戦略的SWOT分析
    Slovensky plynarensky priemysel AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • F-Secure Oyj (FSC1V)：企業の財務・戦略的SWOT分析
    F-Secure Oyj (FSC1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • EnviroMission Limited：電力：M&Aディール及び事業提携情報
    Summary EnviroMission Limited (EnviroMission) is a renewable energy company. It develops solar tower technology (STT). The company owns the license to STT across the world (excluding in China). EnviroMission’s STT uses solar radiation to heat air beneath a translucent canopy to create a solar therma …
  • Groupe Sodiaal：企業の戦略・SWOT・財務情報
    Groupe Sodiaal - Strategy, SWOT and Corporate Finance Report Summary Groupe Sodiaal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • JSC Inter RAO：企業のM&A・事業提携・投資動向
    JSC Inter RAO - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JSC Inter RAO Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Paradigm Biopharmaceuticals Ltd (PAR)：製薬・医療：M&Aディール及び事業提携情報
    Summary Paradigm Biopharmaceuticals Ltd (Paradigm Biopharma) is a biopharmaceutical company. The company focused on research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma …
  • Alon USA Energy Inc (ALJ)-石油・ガス分野：企業M&A・提携分析
    Summary Alon USA Energy Inc (Alon USA), a subsdiary of Delek US Holdings, Inc., is a refiner and marketer of petroleum products. The products offered by the company include various grades of gasoline, diesel fuel, jet fuel, petrochemicals, petrochemical feedstocks, asphalt, and other petroleum-based …
  • El Paso Electric Company (EE)-エネルギー分野：企業M&A・提携分析
    Summary El Paso Electric Company (El Paso) is a vertically integrated electric utility which generates, transmits, and distributes electric power. It produces electricity from nuclear, natural gas, coal, and solar sources. The company has ownership interest in and operates various power generation f …
  • Medivir AB：企業のM&A・事業提携・投資動向
    Medivir AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Medivir AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Daihatsu Motor Co Ltd：戦略・SWOT・企業財務分析
    Daihatsu Motor Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Daihatsu Motor Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nonlinear Dynamics Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Nonlinear Dynamics Ltd (Nonlinear Dynamics), a subsidiary of Waters Corp is a data analysis software development company that provides analysis software products. The company offers products such as Progenesis CoMet that analyses LC-MS and GC-MS data to discover and quantify compounds. It re …
  • Volkswagen AG (VOW3)：企業の財務・戦略的SWOT分析
    Volkswagen AG (VOW3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Wirtgen GmbH：企業の戦略・SWOT・財務分析
    Wirtgen GmbH - Strategy, SWOT and Corporate Finance Report Summary Wirtgen GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆